Acute hepatitis C in Brazil: Results of a national survey

Journal of Medical Virology

Volumn 83, Issue 10, 2011, Pages 1738-1743

  Ferreira, Adalgisa de Souza Paiva ^a   Perez, Renata de Mello ^b   Ferraz, Maria Lucia Gomes ^c   Lewis Ximenez, Lia Laura ^d   Pereira, João Luis ^e   de Almeida, Paulo Roberto Lerias ^f   de Mattos, Angelo Alves ^g  

^a FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e General Hospital of Bonsucesso   (Brazil)

^f HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^g UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Acute hepatitis C; Brazil; Epidemiology; HCV; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ACUTE HEPATITIS C; ADULT; AGED; ARTICLE; BRAZIL; CHRONIC KIDNEY FAILURE; DISEASE COURSE; FEMALE; GENOTYPE; HEALTH SURVEY; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; QUESTIONNAIRE; RISK FACTOR; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BRAZIL; CROSS INFECTION; FEMALE; HEALTH SURVEYS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; JAUNDICE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; RNA, VIRAL; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 80051589771     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22175     Document Type: Article

References (30)

1. Alberti A, Bocatto S, Vario A, Bevegnú L. 2002. Therapy of acute hepatitis C. Hepatology 36: S195-S200.
2. Al-Harbi ASB, Malik GH, Subaity Y, Mansy H, Abutaleb N. 2005. Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transpl 16: 293-297.
3. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, Quaglia S, De Blasi T, Romano P, Traverso A, Leo G, Carbone R, Del Mastro B, Tinelli M, Caramello P, Di Perri G. 2007. A short course of pegylated interferon in acute HCV hepatitis. J Viral Hepat 14: 116-121.
4. Cox AL, Page K, Bruneau J, Shoukry NH, Lauer GM, Kim AY, Rosen HR, Hadziewzicz H, Grakoui A, Fierer DS, Branch AD, Kaplan DE, Chang KM. 2009. Rare birds in North America: Acute hepatitis C cohorts. Gastroenterology 136: 26-31.
5. Engel M, Malta FM, Gomes MM, Mello IM, Pinho JR, Ono-Nita SK, Carrilho FJ. 2007. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Publ Health 7: 50.
6. Fabrizi F, Messa P, Martin P. 2008. Transmission of hepatitis C virus infection in hemodialysis: Current concepts. Int J Artif Organs 31: 1004-1016.
7. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. 2003. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80-88.
8. Heller T, Rehermann B. 2005. Acute hepatitis C: A multifaceted disease. Semin Liver Dis 25: 7-17.
9. Hussein MM, Mooij JM, Hegazy MF, Bamaga MS. 2007. The impact of polymerase chain reaction assays for detection of hepatitis C virus infection in a hemodialysis unit. Saudi J Kidney Dis Transpl 18: 107-113.
10. Irving WL, Salmon D, Boucher C, Hoepelman IM. 2008. Acute HCV virus infection. Eurosurveillance 13: 1-4.
11. Ishii S, Koziel MJ. 2008. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 128: 133-147.
12. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP, German Acute Hepatitis C Therapy Group. 2001. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345: 1452-1457.
13. Kalantar-Zadeh K, Miller LG, Daar ES. 2005. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 46: 290-300.
14. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa Kel S, Madwar MM, Koziel MJ. 2004. Pegylated interferon therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39: 1721-1731.
15. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil, Khalifa A, He KE, Koziel Q, El MJ, Naggar KM, Rasenack J, Afdhal NH. 2006a. Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response. Gastroenterology 130: 632-638.
16. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, El Gohary LA, Ramy AH, Madwar MA, Rasenack J, Afdhal NH. 2006b. Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology 43: 923-931.
17. Kamal SM. 2008. Acute hepatitis C: A systematic review. Am J Gastroenterol 103: 1283-1297.
18. + T lymphocyte responses are induced during acute hepatitis C infection but are not sustained. Eur J Immunol 30: 2479-2487.
19. Licata A, Di Bona D, Schepis F, Sharied L, Craxi A, Cammà C. 2003. When and how to treat acute hepatitis C? J Hepatol 39: 1056-1062.
20. Martínez-Bauer E, Forns X, Armelles M, Planas R, Solà R, Vergara M, Fàbregas S, Vega R, Salmerón J, Diago M, Sánchez-Tapias JM, Bruguera M, Spanish Acute HCV Study Group. 2008. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 48: 20-27.
21. Micaleff JM, Kaldor JM, Dore GJ. 2006. Spontaneous virus clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Hepatol 13: 34-41.
22. Moreira R, Pinho JR, Fares J, Oba IT, Cardoso MR, Caraceni CP, Granato CR. 2003. Prospective study of hepatitis C virus infection in hemodialysis patients by monthly analysis of HCV RNA and antibodies. Can J Microbiol 49: 503-507.
23. Okuda K, Kayashi H, Yokoseki K, Kobayashi S, Kashima T, Irie Y. 1998. Acute hepatitis C among renal failure patients on chronic haemodialysis. J Gastroenterol Hepatol 13: 62-67.
24. Rocha CM, Perez RM, Narciso JL, Ferreira AP, Lemos LB, Medina-Pestana JO, Silva AE, Ferraz M. 2007. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: Efficacy and tolerance. Eur J Gastroenterol Hepatol 19: 119-123.
25. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Francavilla R, Pastore G. 2005. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 42: 329-333.
26. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, Babudieri S, Toti M, Francavilla R, Ancarani F, Antonucci G, Scotto G, Di Marco V, Pastore G, Stroffolini T. 2006. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 43: 1154-1159.
27. Santantonio T, Wiegand J, Gerlach JT. 2008. Acute hepatitis C: Current status and remaining challenges. J Hepatol 49: 625-633.
28. Sharaf Eldin N, Ismail S, Mansour H, Rekacewicz C, El-Houssinie M, El-Kafrawy S, El Aidi S, Abdel-Hamid M, Esmat G, Pol S, Fontanet A, Mohamed MK. 2008. Symptomatic acute hepatitis C in Egypt: Diagnosis, spontaneous viral clearance, and delayed treatment with 12 Weeks of pegylated interferon Alfa-2a. PLoS ONE 3: e4085.
29. Wasley A, Grytdal S, Gallagher K. 2008. Surveillance for acute viral hepatitis - United States 2006. MMWR Surveill Summ 57: 1-24.
30. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP, German HEP-NET Acute HCV Study Group. 2006. Early monotherapy with pegylated interferon alpha- for acute hepatitis C infection: The HEP-NET acute-HCV-II study. Hepatology 43: 250-256.